Keyword: George Yancopoulos
Regeneron's George Yancopoulos won a bonus of sorts in 2012, and now he's vested. This year, though, he and CEO Len Schliefer took a small cut.
The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.
Regeneron CEO Len Schleifer has been at or near the top of the biopharma executive-pay charts for years. That’s still the case for 2016, but not by as wide a margin.
Allergan CEO Brent Saunders recently told investors that his company isn’t looking for any more “transformational” M&A. But on the chance a merger does put him out of a job? A mammoth goodbye present awaits.
Once again, Regeneron CEO Leonard Schleifer and his R&D chief George Yancopoulos are among the highest-paid executives in the industry, with $47.5 million and $40.3 in 2015 compensation.